• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pembrolizumab in HER2-Positive Gastric Cancer.

作者信息

Janjigian Yelena Y, Kawazoe Akihito, Bai Yuxian, Xu Jianming, Lonardi Sara, Metges Jean Phillipe, Yañez Patricio, Wyrwicz Lucjan S, Shen Lin, Ostapenko Yuriy, Bilici Mehmet, Chung Hyun Cheol, Shitara Kohei, Qin Shukui, Van Cutsem Eric, Tabernero Josep, Luo Suxia, Mahave Mauricio, Tang Yong, Lowery Maeve, Monteiro Maria M F, Xu Linzhi, Shih Chie-Schin, Sharan Kanu P, Bhagia Pooja, Rha Sun Young

机构信息

Memorial Sloan Kettering Cancer Center, New York, NY

National Cancer Hospital East, Kashiwa, Japan.

出版信息

N Engl J Med. 2024 Oct 10;391(14):1360-1362. doi: 10.1056/NEJMc2408121. Epub 2024 Sep 14.

DOI:10.1056/NEJMc2408121
PMID:39282917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11620791/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33a1/11620791/22331e7361ef/nihms-2017218-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33a1/11620791/22331e7361ef/nihms-2017218-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33a1/11620791/22331e7361ef/nihms-2017218-f0001.jpg

相似文献

1
Pembrolizumab in HER2-Positive Gastric Cancer.帕博利珠单抗治疗HER2阳性胃癌
N Engl J Med. 2024 Oct 10;391(14):1360-1362. doi: 10.1056/NEJMc2408121. Epub 2024 Sep 14.
2
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.一线帕博利珠单抗联合曲妥珠单抗治疗人表皮生长因子受体 2（HER2）阳性食管、胃或胃食管交界处癌：一项开放标签、单臂、2 期临床试验。
Lancet Oncol. 2020 Jun;21(6):821-831. doi: 10.1016/S1470-2045(20)30169-8. Epub 2020 May 18.
3
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.EORTC-1203-GITCG - “创新”试验：曲妥珠单抗单药与曲妥珠单抗加帕妥珠单抗联合化疗在 HER2 阳性胃和胃食管交界处腺癌围手术期治疗中的疗效对比：EORTC 胃肠道肿瘤研究组、韩国癌症研究组和荷兰上消化道肿瘤组的一项随机 II 期分组试验。
BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4.
4
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.一线帕博利珠单抗/安慰剂联合曲妥珠单抗和化疗治疗 HER2 阳性晚期胃癌：KEYNOTE-811 研究。
Future Oncol. 2021 Feb;17(5):491-501. doi: 10.2217/fon-2020-0737. Epub 2020 Nov 10.
5
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.帕妥珠单抗联合曲妥珠单抗和化疗治疗人表皮生长因子受体 2 阳性转移性胃或胃食管交界腺癌（JACOB）：一项双盲、随机、安慰剂对照的 3 期研究的最终分析。
Lancet Oncol. 2018 Oct;19(10):1372-1384. doi: 10.1016/S1470-2045(18)30481-9. Epub 2018 Sep 11.
6
[Pembrolizumab+chemotherapy as first-line treatment in patients with HER2 negative advanced oesogastric adenocarcinoma].帕博利珠单抗联合化疗作为HER2阴性晚期食管胃腺癌患者的一线治疗方案
Bull Cancer. 2024 May;111(5):431-432. doi: 10.1016/j.bulcan.2024.01.004. Epub 2024 Mar 7.
7
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).Ipilimumab 或 FOLFOX 联合 Nivolumab 和 Trastuzumab 治疗未经治的 HER2 阳性局部晚期或转移性胃食管腺癌 - 随机 2 期 INTEGA 试验（AIO STO 0217）。
BMC Cancer. 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3.
8
[Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].帕博利珠单抗联合曲妥珠单抗及化疗用于HER2过表达且CPS≥1的晚期或转移性胃或胃食管交界腺癌
Bull Cancer. 2024 Feb;111(2):130-132. doi: 10.1016/j.bulcan.2023.11.004. Epub 2023 Dec 8.
9
Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer.替奈妥单抗联合 S-1 和奥沙利铂作为人表皮生长因子受体 2 阳性胃癌的一线治疗。
World J Gastroenterol. 2024 Oct 28;30(40):4367-4375. doi: 10.3748/wjg.v30.i40.4367.
10
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study.一线帕博利珠单抗联合化疗治疗HER2阴性晚期胃癌：随机3期KEYNOTE-859研究的中国亚组分析
Adv Ther. 2025 Apr;42(4):1892-1906. doi: 10.1007/s12325-024-03069-4. Epub 2025 Mar 1.

引用本文的文献

1
ERBB3 influences the ferroptosis pathway via modulation of lipid peroxidation and GSH synthesis in gastric cancer.ERBB3通过调节胃癌中的脂质过氧化和谷胱甘肽合成来影响铁死亡途径。
Cell Death Discov. 2025 Aug 22;11(1):398. doi: 10.1038/s41420-025-02707-2.
2
Conversion Surgery After Trastuzumab-Based Chemotherapy and Immunotherapy for Stage IV HER2-Positive Gastric Cancer: A Retrospective Multicenter Cohort Study.曲妥珠单抗为基础的化疗和免疫治疗后IV期HER2阳性胃癌的转化手术：一项回顾性多中心队列研究
Ann Surg Oncol. 2025 Jun 26. doi: 10.1245/s10434-025-17729-4.
3
New tool in the toolbox: patient selection for zolbetuximab in advanced treatment-naïve gastric/gastroesophageal junction adenocarcinoma.

本文引用的文献

1
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.帕博利珠单抗联合曲妥珠单抗和化疗治疗 HER2 阳性胃或胃食管交界腺癌：来自 3 期 KEYNOTE-811 随机安慰剂对照试验的中期分析。
Lancet. 2023 Dec 9;402(10418):2197-2208. doi: 10.1016/S0140-6736(23)02033-0. Epub 2023 Oct 20.
2
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.KEYNOTE-811 试验：双 PD-1 和 HER2 阻断在 HER2 阳性胃癌中的应用。
Nature. 2021 Dec;600(7890):727-730. doi: 10.1038/s41586-021-04161-3. Epub 2021 Dec 15.
工具箱中的新工具：初治晚期胃/胃食管交界腺癌中zolbetuximab的患者选择
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf185.
4
Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer.围手术期双重PD-1和HER2阻断在HER2阳性胃癌中的安全性和疗效
Cell Rep Med. 2025 Jun 17;6(6):102190. doi: 10.1016/j.xcrm.2025.102190.
5
Advancements and challenges in immunotherapy for gastric cancer: current approaches and future directions.胃癌免疫治疗的进展与挑战：当前方法与未来方向
Front Immunol. 2025 May 21;16:1592733. doi: 10.3389/fimmu.2025.1592733. eCollection 2025.
6
Novel immunotherapy for gastric cancer: targeting the CD47-SIRPα axis.胃癌的新型免疫疗法：靶向CD47-SIRPα轴。
Cancer Metastasis Rev. 2025 May 29;44(2):52. doi: 10.1007/s10555-025-10269-z.
7
Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings.曲妥珠单抗德鲁昔单抗用于三线及以上治疗HER2阳性晚期胃癌患者时早期肿瘤缩小对生存结局的影响。
Therap Adv Gastroenterol. 2025 Apr 24;18:17562848251333538. doi: 10.1177/17562848251333538. eCollection 2025.
8
Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial.HER2阳性胃癌中帕博利珠单抗序贯曲妥珠单抗联合铂类/5-氟尿嘧啶治疗反应的决定因素：一项II期化学免疫治疗试验
Clin Cancer Res. 2025 Apr 14;31(8):1476-1490. doi: 10.1158/1078-0432.CCR-24-3528.
9
Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).2025年食管癌生物标志物：西班牙医学肿瘤学会（SEOM）和西班牙病理学会（SEAP）的最新共识声明
Clin Transl Oncol. 2025 Mar 12. doi: 10.1007/s12094-025-03865-6.
10
Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights.人表皮生长因子受体2阳性晚期胃癌或食管胃腺癌：回顾过去以获得新见解
Curr Oncol Rep. 2025 Jan;27(1):15-29. doi: 10.1007/s11912-024-01626-2. Epub 2025 Jan 3.